Unicycive Therapeutics, Inc., (UNCY): Price and Financial Metrics
UNCY Price/Volume Stats
| Current price | $1.38 | 52-week high | $2.87 |
| Prev. close | $1.39 | 52-week low | $0.40 |
| Day low | $1.36 | Volume | 18,087 |
| Day high | $1.40 | Avg. volume | 3,558,688 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $0.96 | Market Cap | 21.05M |
UNCY Stock Price Chart Interactive Chart >
Unicycive Therapeutics, Inc., (UNCY) Company Bio
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Latest UNCY News From Around the Web
Below are the latest news stories about UNICYCIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate UNCY as an investment opportunity.
Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit OutlookUnicycive Therapeutics, Inc. ( NASDAQ:UNCY ) is possibly approaching a major achievement in its business, so we would... |
Unicycive Announces First Quarter 2023 Financial Results and Provides Business UpdateClosed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones Continued progress with plan to file New Drug Application with the U.S. Food and Drug Administration in Q3 2023, with the potential for approval and launch in 2024 LOS ALTOS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnol |
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association CongressData highlights the potential safety and reno-protective effect of UNI-494LOS ALTOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced that two datasets highlighting the safety and suggestive efficacy of UNI-494 in animal models were accepted for oral presentation at the upcoming 60th European Renal Association Congress (ERA 2023) taking place f |
Unicycive Announces Full Year 2022 Financial Results and Provides Business UpdateClosed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Financing by new and existing institutional investors from high-profile healthcare-focused funds to support launch and commercialization of investigational new drug, Renazorb™ Company on track to file New Drug Application with the U.S. Food and Drug Administration in mid-2023 with potential for approval and launch in 2024 LOS ALTOS, Calif., March |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off the day with an overview of the biggest pre-market stock movers investors need to keep an eye on for Tuesday! |
UNCY Price Returns
| 1-mo | 11.29% |
| 3-mo | 181.63% |
| 6-mo | 97.14% |
| 1-year | 52.35% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 155.56% |
| 2022 | -73.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...